Safety of LMA intubation on GERD occurance during RFCA procedures under general anesthesia : Pilot study

Safety of Laryngeal mask airway(LMA) intubation on Gastroesophageal reflux disease(GERD) occurance during Radiofrequency catheter ablation(RFCA) procedures under general anesthesia : Pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003370

Enrollment

Registered

2018-11-23

Start date

2019-02-01

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : Insert the ST probe (catheter for aspiration and esophageal thermometer) into the two holes of the protector. One probe is located between the left upper pulmonary vein and the lef

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult patients with American Society of Anesthesiologists Classification class I-IV (aged 19-70 years) 2) Patients who underwent radiofrequency catheter ablation for the first time after diagnosis of atrial fibrillation under general anesthesia 3) Frequency Scale for Symptoms of Gastroesophageal reflux disease (GERD) (FSSG) Patients without prior gastroesophageal reflux disease (GERD) symptom

Exclusion criteria

Exclusion criteria: 1) Children (under 19 years old) 2) Patients with a high likelihood of lung aspiration 3) Patients with unstable vital signs 4) Patients with liver or kidney disease 5) Patients with metabolic diseases 6) Emergency surgery 7) Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
The rate at which the pH of LMA tip decreases to 4 or less	—

Secondary

Measure	Time frame
The rate at which the pH of low esophageal junction decreases to 4 or less;The rate at which the pH of mid esophageal junction decreases to 4 or less	—

Countries

Korea, Republic of

Contacts

Public ContactJin hee ahn

Samsung Medical Center

blattblatt@naver.com+82-2-3410-2470

Outcome results